Evaluation of the effect of a 0.0584 % hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis

• Published in: Journal of veterinary science (Suwŏn-si, Korea) 2012, 13(2), , pp.187-191
• Main Authors: Nam, E.H., Seoul National University, Seoul, Republic of Korea, Park, S.H., Seoul National University, Seoul, Republic of Korea, Jung, J.Y., Seoul National University, Seoul, Republic of Korea, Han, S.H., Seoul National University, Seoul, Republic of Korea, Youn, H.Y., Seoul National University, Seoul, Republic of Korea, Chae, J.S., Seoul National University, Seoul, Republic of Korea, Hwang, C.Y., Seoul National University, Seoul, Republic of Korea
• Format: Article
• Language: English
• Subjects: Administration, Topical; Animals; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - therapeutic use; atopic dermatitis; canine; CHIEN; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - pathology; Dermatitis, Atopic - veterinary; Dog Diseases - drug therapy; Dog Diseases - pathology; DOGS; Female; Hydrocortisone - administration & dosage; Hydrocortisone - analogs & derivatives; Hydrocortisone - therapeutic use; hydrocortisone aceponate; Male; Original; PERRO; transepidermal water loss; 수의학
• ISSN: 1229-845X; 1976-555X
• DOI: 10.4142/jvs.2012.13.2.187

The purpose of this study was to evaluate the effects of a topical spray containing 0.0584% hydrocortisone aceponate (HCA) on canine atopic dermatitis (CAD) and to evaluate the skin barrier function during the treatment of CAD. Twenty-one dogs that fulfilled the diagnostic criteria for CAD were included in this study. The HCA spray was applied once a day to the lesions of all dogs for 7 or 14 days. Clinical assessment was performed before (day 0) and after treatment (day 14), and clinical responses were correlated with changes in skin barrier function. CAD severity significantly decreased after 14 days of HCA treatment based on the lesion scores (p less than 0.0001), which were determined using the CAD extent and severity index (CADESI-03) and pruritus scores (p less than 0.0001) calculated using a pruritus visual analog scale. Transepidermal water loss, a biomarker of skin barrier function, was significantly reduced compared to baseline (day 0) measurements (p = 0.0011). HCA spray was shown to be effective for significantly improving the condition of dogs suffering from CAD. This treatment also significantly improved cutaneous hydration and skin harrier function in the animals.